Peer-reviewed veterinary case report
Lower-dose twice-daily trilostane helps dogs with hyperadrenocorticism
By Feldman, Edward C·Published in Journal of the American Veterinary Medical Association·2011·Department of Medicine and Epidemiology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
- Species:
- dog
Plain-English summary
A group of 47 dogs with hyperadrenocorticism (a condition causing excessive cortisol) was treated with a lower-dose medication called trilostane, given twice daily. After two months, many dogs showed good responses to the treatment, especially those with tumors, who also underwent successful surgery to remove the tumors. For dogs with a different form of the condition, most maintained good health without needing higher doses, although some did require adjustments over time. While a few dogs experienced side effects, only one needed to be hospitalized. Overall, the lower-dose trilostane was effective for managing this condition in dogs.
People also search for: dog hyperadrenocorticism treatment · trilostane side effects in dogs · dog Cushing's disease medication
Abstract
OBJECTIVE: To evaluate effectiveness and incidence of adverse reactions to twice-daily lower-dose oral administration of trilostane in the treatment of dogs with naturally occurring hyperadrenocorticism (NOH). DESIGN: Clinical trial. ANIMALS: 47 dogs with NOH. PROCEDURES: 47 dogs were treated orally with trilostane (0.21 to 1.1 mg/kg [0.1 to 0.5 mg/lb], q 12 h). All dogs were reevaluated at 2 weeks and 2 months, 38 dogs at 6 months, and 28 dogs at 1 year of treatment. RESULTS: 9 of 47 dogs had an adrenocortical tumor causing NOH, and all had good responses after 2 months (mean trilostane dosage, 0.89 mg/kg [0.40 mg/lb], q 12 h). All successfully underwent surgical adrenal tumor extirpation. Thirty-eight dogs had pituitary-dependent hyperadrenocorticism (PDH); 15 dogs did not require a dose increase during the study, and at each of 4 reevaluations, 10 of 15, 13 of 15, 14 of 15, and 11 of 11 had a good response. Twenty-three dogs with PDH had their dose or frequency of trilostane administration increased during the study. Mean trilostane dosage at 1-year reevaluation in dogs with a good response was 1.7 mg/kg (0.8 mg/lb), twice daily, or 1.1 mg/kg, 3 times daily. At each of 4 reevaluations, 17 of 23, 14 of 23, 17 of 23, and 13 of 17 dogs with PDH had a good response. Five dogs became ill because of trilostane-induced adverse effects, but only 1 required hospitalization. CONCLUSIONS AND CLINICAL RELEVANCE: Administration of initial lower doses of trilostane to dogs with NOH is effective.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21627507/